NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.

The firm will use the proceeds to advance its platform technology, R&D, and pre-commercialization activities for its base-editing drugs.

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

The firms are combining forces to get their cancer screening and diagnostic platforms into more hospitals in the US.

NEW YORK – Hutchmed on Thursday said it has completed enrollment of a Phase II trial in China testing the FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma ...

NEW YORK – Contract research organization Anova Enterprises on Wednesday said that patients with newly diagnosed high-grade glioma are starting to receive Denovo Biopharma's gene therapy DB107 in a ...

The first patient, who had xerostomia linked with Sjögren's disease, received the autologous cell therapy as part of a Phase ...

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology ...

NEW YORK – Memorial Sloan Kettering Cancer Center has built a data infrastructure that now represents 140,000 tumor samples and 100,000 cancer patients and is using it to train machine learning models ...

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...